Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Šečerov Ermenc Ajra) .

1 - 10 / 27
First pagePrevious page123Next pageLast page
1.
Preoperative treatment with radiochemotherapy for locally advanced gastroesophageal junction cancer and unresectable locally advanced gastric cancer
Ivica Ratoša, Irena Oblak, Franc Anderluh, Vaneja Velenik, Jasna But-Hadžić, Ajra Šečerov Ermenc, Ana Jeromen, 2015, original scientific article

Abstract: To purpose of the study was to analyze the results of preoperative radiochemotherapy in patients with unresectable gastric or locoregionally advanced gastroesophageal junction (GEJ) cancer treated at a single institution. Between 1/2004 and 6/2012, 90 patients with locoregionally advanced GEJ or unresectable gastric cancer were treated with preoperative radiochemotherapy at the Institute of Oncology Ljubljana. Planned treatment schedule consisted of induction chemotherapy with 5-fluorouracil and cisplatin, followed by concomitant radiochemotherapy four weeks later. Three-dimensional conformal external beam radiotherapy was delivered by dual energy (6 and 15 MV) linear accelerator in 25 daily fractions of 1.8 Gy in 5 weeks with two additional cycles of chemotherapy repeated every 28 days. Surgery was performed 4-6 weeks after completing radiochemotherapy. Following the surgery, multidisciplinary advisory team reassessed patients for the need of adjuvant chemotherapy. The primary endpoints were histopathological R0 resection rate and pathological response rate. The secondary endpoints were toxicity of preoperative radiochemotherapy and survival. Treatment with preoperative radiochemotherapy was completed according to the protocol in 84 of 90 patients (93.3%). Twenty patients (22.2%) did not undergo the surgery because of the disease progression, serious comorbidity, poor performance status or still unresectable tumour. In 13 patients (14.4%) only exploration was performed because the tumour was assessed as unresectable or diffuse peritoneal carcinomatosis was established. Fifty-seven patients (63.4%) underwent surgery with the aim of complete removal of the tumour. Radical resection was achieved in 50 (55.6%) patients and the remaining seven (7.8%) patients underwent non-radical surgery (R1 in five and R2 in two patients). In this group of patients (n = 57), pathological complete response of tumour was achieved in five patients (5.6% of all treated patients or 8.8% of all operated patients). Down-staging was recorded in 49 patients (86%), in one patient (1.8%) the stage after radiochemotherapy was unchanged while in seven patients (12.3%) the pathological stage was higher than clinical, mainly due to higher pN stage. No death was recorded during preoperative radiochemotherapy. Most grade 3 and 4 toxicities were due to vomiting, nausea and bone marrow suppression (granulocytopenia). Twentysix (45.6%) patients died due to GEJ or gastric carcinoma, one died because of septic shock following the surgery and a reason for two deaths was unknown. Twenty-eight patients (49.1%) were disease free at the time of analysis, while 29 patients (50.9%) developed the recurrence, mostly as distant metastases. At two years, locoregional control, diseasefree survival, disease-specific survival and overall survival were 82.9%, 43.9%, 56.9% and 53.9%, respectively. Preoperative radiochemotherapy was feasible in our group of patients and had acceptable toxicity. Majority of patients achieved down-staging, allowing greater proportion of radical resections (R0), which are essential for patientsʼ cure.
Keywords: neoadjuvant radiochemotherapy, perioperative chemotherapy, chemotherapy, adenocarcinoma, carcinoma, surgery
Published in DiRROS: 23.04.2024; Views: 19; Downloads: 2
.pdf Full text (1,18 MB)

2.
Stereotaktična radioterapija za zdravljenje refraktarne prekatne tahikardije: prikaz primerov
Tamara Jarm, Krištof Knap, Bor Antolič, Boštjan Berlot, Rihard Hudej, Aljaša Jenko, Ajra Šečerov Ermenc, Jasna But-Hadžić, Ivica Ratoša, 2023, professional article

Abstract: Stereotaktična radioterapija aritmij (STAR) predstavlja novo in obetavno možnost za bolnike z refraktarno prekatno tahikardijo, ki je odporna proti konvencionalnim metodam zdravljenja. STAR omogoča natančno neinvazivno ablacijo aritmogenega substrata ob minimalni prizadetosti sosednjih organov. Ta metoda zdravljenja je uporabna za bolnike, pri katerih je tarčno tkivo s katetrsko ablacijo nedosegljivo, pogosti šoki implantabilnega kardioverter-defibrilatorja pa močno nižajo njihovo kakovost življenja ali kadar sta ti metodi zdravljenja zaradi slabega zdravstvenega stanja kontraindicirani. Tarčo obsevanja (predel levega prekata) natančno opredelimo s predhodno slikovno diagnostiko, elektrokardiogramom, posnetki prekatne tahikardije in po potrebi invazivnim ali neinvazivnim elektrofiziološkim mapiranjem srca. Po pripravi na obsevanje na simulatorju sledi enkratno obsevanje z visokim odmerkom 25 Gy, ki je trenutno edina standardna frakcionacija. Bolniki obsevanje dobro prenašajo. Dosedanje raziskave so poročale o dobri učinkovitosti zdravljenja z bistvenim zmanjšanjem pogostosti epizod prekatne tahikardije in brez večjih neželenih učinkov. Poročamo o prvi skupini štirih bolnikov z visokorizično refraktarno prekatno tahikardijo, ki so bili zdravljeni s stereotaktično radioterapijo na Onkološkem inštitutu Ljubljana. Izvedba STAR se je izkazala kot učinkovita metoda z nizko stopnjo akutnih neželenih učinkov in predstavlja novo možnost obravnave te ranljive skupine bolnikov v slovenskem prostoru.
Keywords: stereotaktična radioterapija, aritmije, prekatna tahikardija, radioablacija srca
Published in DiRROS: 26.02.2024; Views: 113; Downloads: 34
.pdf Full text (146,07 KB)

3.
Oligometastatski rak debelega črevesa in danke : prikaz primera
Luka Puzigaća, Ajra Šečerov Ermenc, 2022, published scientific conference contribution

Abstract: Rak debelega črevesa in danke lahko napreduje v oligometastatsko bolezen. Napredki v zgodnjem odkrivanju in intenzivnem sistemskem zdravljenju omogočajo čedalje boljše odgovore na zdravljenje in dolgoročno sistemsko kontrolo bolezni. Pojavlja se vprašanje dolgoročnega vodenja oligometastatskih bolnikov. Kirurška resekcija zasevkov lahko pripomore k izboljšanem preživetju, omogoča kurativnost posega ali podaljša interval brez sistemskega zdravljenja, je pa pogosto omejena z anatomijo, invazivnostjo in morbiditeto takšnega pristopa. Stereotaktično obsevanje (SBRT) zasevkov omogoča zelo učinkovito in natančno zdravljenje zasevkov v nizkem številu obsevalnih odmerkov in s tem zelo dobro in dolgoročno lokalno kontrolo z minimalno invazivnostjo in morbidnostjo. Ta prikaz primera prikazuje zgodbo bolnika, zdravljenega na Onkološkem inštitutu v Ljubljani.
Keywords: rak debelega črevesa in danke, onkološko zdravljenje, rak prebavil
Published in DiRROS: 13.01.2023; Views: 490; Downloads: 96
.pdf Full text (85,86 KB)

4.
5.
Prognostične vrednosti klasifikacije oligometastatske bolezni
Ajra Šečerov Ermenc, 2022, published professional conference contribution

Keywords: oligometastatski raki, onkološki bolniki, obsevanje, sistemsko zdravljenje
Published in DiRROS: 14.12.2022; Views: 340; Downloads: 219
.pdf Full text (20,40 MB)
This document has many files! More...

6.
Oligometastatski rak
Ivica Ratoša, Karmen Stanič, Tanja Ovčariček, Ajra Šečerov Ermenc, Janka Čarman, Blaž Grošelj, Staša Jelerčič, Peter Korošec, Manja Šešek, Marko Kokalj, Gaber Plavc, Miha Oražem, Helena Barbara Zobec Logar, 2022, review article

Abstract: Oligometastatska bolezen (OMB) predstavlja vmesno stanje med lokalno napredovalo boleznijo in obsežnejšo metastatsko boleznijo. Zaenkrat ne poznamo specifičnih biomarkerjev, ki bi nam pomagali opredeliti bolnike z majhnim bremenom bolezni, zato diagnoza OMB temelji na slikovni diagnostiki. V zadnjih letih narašča zanimanje za optimizacijo zdravljenja OMB predvsem zaradi obetavnih rezultatov dodatka lokalnega k obstoječemu sistemskemu zdravljenju. S takšnim načinom zdravljenja se je prvič pokazala možnost doseganja dolgotrajnih zazdravitev ali redko celo ozdravitev teh bolnikov. Razlikovanje posameznih vrst OMB in njihovo enotno poimenovanje je pomembno zlasti v kliničnih raziskavah, saj nam omogoča medsebojno primerjavo rezultatov različnih raziskav.
Keywords: klasifikacija, oligometastatska bolezen, sistemsko zdravljenje, onkologija
Published in DiRROS: 06.12.2022; Views: 501; Downloads: 134
.pdf Full text (246,61 KB)

7.
8.
Oligometastatska bolezen in stereotaktično obsevanje
Ajra Šečerov Ermenc, 2020, published professional conference contribution

Keywords: stereotaktično obsevanje, radioterapija, obsevalne tehnike
Published in DiRROS: 13.04.2022; Views: 484; Downloads: 160
.pdf Full text (230,41 KB)

9.
Primerjava razlik med vrisovalci pri določanju tumorskega tarčnega volumna pri raku požiralnika na MR, CT in PET CT
Ajra Šečerov Ermenc, Barbara Šegedin, 2021, published scientific conference contribution

Keywords: rak požiralnika, tarčni volumen, obsevanje
Published in DiRROS: 04.04.2022; Views: 494; Downloads: 168
.pdf Full text (91,50 KB)

10.
Imunoterapija in obsevanje pri gastrointestinalnih rakih
Ajra Šečerov Ermenc, 2021, published professional conference contribution

Keywords: imunoterapija, radioterapija, onkološko zdravljenje
Published in DiRROS: 29.03.2022; Views: 466; Downloads: 215
.pdf Full text (78,57 KB)
This document has many files! More...

Search done in 0.33 sec.
Back to top